Over 900 extra GPs needed over 15 years to meet demand

At least 940 additional general practitioners will be required to meet expected demand over the next 15 years, according to research from the Economic and Social Research Institute (ESRI).
It says a growing, and to a lesser extent, an ageing population, is behind the reasons for the projected increase in demand for GP services of between 23% and 30% by 2040.
It is also expected that demand for general practice nurses will rise in that timeframe.
GP Chair of the Irish Medical Organisation, and GP in Kilkenny, Tadhg Crowley, has said Covid-19 interrupted medical practice and made it busier, but things are returning to what is normal.
Speaking on RTÉ's Morning Ireland, he said general practice is a "great career option" but has "not been seen in this way" in recent years.
"It's a great job. Anyone who's considering medicine, I'd always say general practice is a fabulous job to be in. We're facing challenges and ... some of the challenges are age related," he said.
Dr Crowley said the sector had a generation of GPs or prospective GPs, wiped out by the Financial Emergency Measures in Public Interests (FEMPI) cuts about 15 years ago, which put people off going into general practice.
"So we're starting recovering from that. In terms of job satisfaction, it's still a fabulous job, but I suppose we are facing challenges," he added.
He said that Ireland is facing the same problems that the UK faced about 20 years ago and "they got it wrong" and the NHS is failing at general practice level.
Dr Crowley said the Government needs to carefully handle the situation to avoid that scenario.
"We're facing the challenges that the UK faced 20 years ago, so it's going to be really important to have steady hands in the Department of Health and Government. The UK got it wrong.
"The NHS has been destroyed in general practice. And it's really important at this stage that we look at A; the number of medical doctors we trained and B: the number of GPs that we train," he said.
Dr Crowley stressed that 40% of GPs are aged over 60 and the country is at a stage in terms of the GP population "that we are facing a crisis and the number of people that will come through there".
He said as a result, the number of GP training posts has increased to 350, however it is "not going to come close to the number of GPs that we need in the long term".
He said GPs are "at a crossroads" and will have to increase the number of undergraduates trained.
"If you don't train enough GPs, what you have is, and we've seen this in other countries, these pop-up medical clinics that have employed doctors that aren't actually GPs," he added.
Dr Crowley said the long-term effect in the population is "quite poor".
He added that it is a competitive market worldwide for GPs and it is incumbent on those working in the health service to make it an attractive option for graduates.
"It is a competitive market worldwide for doctors and I suppose it's incumbent on those working within the health system here to make sure that it's an attractive area for GPs to come back to.
"And one of the areas, it's very difficult to set up and practice as a young GP and it's something that I think the Government really need to focus down on," he said.
"It's the canary in the mine in terms of general practice, the number of GP lists that are being unfilled at the moment is something that will need to be looked at."

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

The Irish Sun

7 hours ago

• The Irish Sun

Urgent warning over drug taken by millions – as AstraZeneca accused of ‘misreporting' safety data

MEDICS have raised concerns over a drug taken by millions to prevent heart attacks and strokes, claiming key safety data was "misreported" by its manufacturer AstraZeneca. Anti-clotting pill ticagrelor has been available on the NHS in 2011, after trials appeared to show it could prevent one in five deaths after a heart attack. 1 A BMJ investigation has raised concerns over clinical trials that spurred on the approval of ticagrelor, sold as Brilique But Ticagrelor is an antiplatelet medicine that prevents blood cells from sticking together and The twice-daily pill is prescribed to patients with acute coronary syndrome who are at greater risk of blood clots due to a history of In the UK, the drug is prescribed around 45,000 times per month on the NHS. Read more on medication Now, experts claim to have uncovered "evidence of serious misreporting" in two clinical trials that were pivotal to the drug's approval in the UK and US. These findings raise "doubts over the approval and decade long use of ticagrelor", sold as Brilique in the UK, the report authors wrote in the BMJ . In response, an AstraZeneca spokesperson told Sun Health: 'We are confident in the integrity of the trials and its evidence in support for Brilique.' Two AstraZeneca studies, known as ONSET/OFFSET and RESPOND, were published in the leading journal Circulation , reporting the drug's effects on platelet function. Most read in Uncategorized The ONSET/OFFSET trial involved 123 patients and found that ticagrelor was faster and better at preventing clots than a competitor drug. Similar results were published in RESPOND, which involved 98 patients. Early warning sign of heart attack you may notice in bed But the report authors claimed claimed 'primary endpoint' results in the two key trials - which were pivotal in determining the treatment's effectiveness - were inaccurately reported in Circulation . "We found evidence that the trials were inaccurately reported," they said. "In one instance, AstraZeneca's trial failed to show statistical significance, but was published in a leading cardiology journal as significant." It also said around a quarter of the readings from machines used in the trials were not included in the data sets, the US medicine's regulator, the Food and Drug Administration (FDA) used to approve the drug. In order for ticagrelor to get approved, clinical trials had to prove that it was a better drug than competitors in a phase 3 trial. After phase 3 and drug approval, the FDA and MHRA in the UK, continues monitoring it in phase 4 trials, to see if there are any additional problems with the drug. But the BMJ analysis of two phase 2 trial results found there were instances of patients whose blood "platelet aggregation dramatically increased". This is when blood cells stick together to form clumps, which can lead to blood clots - exactly what the drug aims to prevent. Key facts about ticagrelor Ticagrelor is an antiplatelet medicine that prevents platelets - a type of blood cell - from sticking together and forming a dangerous blood clot. Taking ticagrelor can help prevent blood clots if you have an increased risk of having them because you: Have had a heart attack Have unstable angina Have had a stroke or a transient ischaemic stroke (TIA, or mini-stroke) Ticagrelor is only available on prescription. You'll usually take ticagrelor twice a day and it's often prescribed together with low-dose aspirin at the start of treatment. The main side effects of ticagrelor are getting out of breath and bleeding more easily than normal. You may have nosebleeds, heavier periods, bleeding gums and bruising. According to medicines watchdog the National Institute for Health and Care Excellence (NICE), patients are advised to take the drug twice a day at 90mg for around a year after a heart attack. A lower dose of 60mg, may then be prescribed by doctors for up to a further three years. It may also be taken by those who have suffered a minor stroke or a transient ischaemic attack at 90mg alongside aspirin. Sources: NHS, NICE This is "an improbable effect for an anti-platelet drug" and "suggests an incorrect laboratory reading", the BMJ said. Assessing the readings from platelet machines used at the two trial sites, led by cardiologist Dr Paul Gurbel, investigators also found more than 60 of the 282 readings were not included in datasets submitted to the FDA. "The platelet activity levels not entered were significantly higher than those used in the Circulation papers and FDA datasets," they claimed. "It is unclear whose blood was sampled, and why those measurements did not contribute to data in either trial." The report authors conducted their investigation through interviews with trial investigators and platelet experts and access to the underlying trial data submitted to regulators. They also said that principal investigators involved in ticagrelor trials "were unreachable or declined to be interviewed". "The findings raise even deeper questions over the approval and decade long use of the drug," the authors claimed. Dr Victor Serebruany, an expert in cardiovascular pharmacology at Johns Hopkins University in Maryland, who has been critical of the drug for over a decade said: "It's been obvious for years that there is something wrong with the data. "That the FDA's leadership could look past all these problems- on top of the many problems their own reviewers identified and are now being discovered by The BMJ - is unconscionable. "We all need to know how and why that happened. "If doctors had known what happened in these trials, they would never have started using ticagrelor." But a spokesperson for the Sinai Center for Thrombosis Research and Drug Development, which Dr Gurbel leads, told Sun Health has also contacted Circulation for comment. The journal did not respond to the BMJ . How to reduce your risk of heart attacks and stroke You can reduce your risk of heart attack and stroke with many of the same methods. Heart attacks and strokes, although affecting different organs of the body, are both what we call cardiovascular events. Both arise from similar underlying conditions, such as atherosclerosis —a buildup of fatty deposits in the arteries. According to the American Heart Association, the risk factors for heart attacks and strokes are largely the same: high blood pressure, high cholesterol, smoking, obesity, physical inactivity and diabetes. Therefore, addressing these risk factors can simultaneously reduce the risk of both conditions. Here are ways you can prevent the two: Healthy diet More fruit and veg: The DASH, which emphasises fruit, vegetables, whole grains and lean proteins, has been shown to reduce blood pressure and improve heart health. Less fats: Too much saturated and trans fats can raise cholesterol levels and increase the risk of atherosclerosis. Go for healthier fats like those found in olive oil, nuts, and avocados. Limit salt: High salt intake is linked to high blood pressure, a major risk factor for both heart attack and stroke. The NHS recommends no more than 6g of salt per day for adults. Fibre: Foods high in soluble fibre, such as oats and beans, can help lower cholesterol levels. Exercise Walking, running, cycling, swimming - whatever you like, do it! Aerobic exercise can strengthen the heart and improve circulation. The NHS advises at least 150 minutes of moderate-intensity aerobic activity or 75 minutes of vigorous-intensity activity each week. Strength training exercises can help control weight, improve cholesterol levels, and reduce blood pressure. It is recommended twice a week by the NHS. Manage blood pressure Healthy diet and exercise can help keep your blood pressure in check. But it is worth monitoring it yourself after the age of 40, at least, when the NHS invites adults for a check-up every five years. High blood pressure often has no symptoms but significantly increases the risk of heart attack and stroke. Quit smoking One of the best ways to quit smoking is to use resources provided by NHS Smokefree. Support groups, medications, and other tools to help quit smoking such as vapes could be what you need to kick the habit for good - and it's free. Limit booze Excessive alcohol consumption can increase blood pressure and contribute to weight gain, which can snowball and become a heart health risk. The NHS recommends not regularly drinking more than 14 units of alcohol per week.

Irish Examiner

19 hours ago

• Irish Examiner

Why many women are deciding not to have a child

A new National Women's Health Survey, commissioned by the Irish Examiner and carried out by market researchers Ipsos B&A, found that, among women who are currently pregnant or who have had a child, one in five experienced fertility difficulties. Four in five of these women sought medical advice in relation to their infertility or their partner's, while 52% underwent fertility treatment such as IVF. A total of 1,078 women aged 18 and above responded to the survey. While 45% of the women who had had a child said they plan to have another, 49% said they don't want to. Galway woman Serena Matthew, who is in her early 40s, falls into that cohort: 'Two children were always in my head as an [ideal] number. I now have an 11-year-old girl and a 14-year-old boy. My husband would have loved a third, but we decided that after our second, it just wasn't an option.' Their decision was based on their finances. 'We saw the cost involved in bringing up two children. We've a four-bed house and the fourth bedroom is small, so we didn't have the space. Moving wasn't an option with prices going up. Two is what we could handle. We didn't want to put ourselves in a difficult position financially.' Matthew is not alone in her position. More than one in three National Women's Health Survey respondents report not feeling financially in a position to have a child, or another child. 11% disagree, and a large number 'don't know' or are unsure. Dr Dora Tuda, an ESRI research officer is not surprised by the finding that one-quarter of all women say they have delayed, or will delay, having children until they have reached certain financial or career goals — a thinking more characteristic of middle-class women. Tuda points out that nowadays, in Ireland, the EU and the US, more women than men hold a third-level degree: 'In Europe in 2022, 48% of women held a third-level degree compared to 37% of men. Why do people get a higher-level degree? To get a better job, a higher income. So if women are considering having a child, they also need to think about leaving the labour market for a while, which corresponds to some income loss.' While acknowledging that it sounds harsh, Tuda highlights what economists refer to as a 'child penalty' — the pay cut that having a child involves and that falls disproportionately on women. 'Even in Scandinavian countries — [considered] more 'equal' than other countries — women on average experience a 20% income loss after having a child compared to men with the same experience and qualifications. This is because of maternity leave — once they return to work, it takes time to catch up. They may lose chances of promotion.' Dr Dora Tuda, a research officer with the ESRI. Equality in leave In Ireland, parental leave is set up so women are more likely to take leave after having a child — 26 weeks paid maternity leave compared to two weeks paid paternity leave for fathers. 'The system is [such] that the income loss from having a child is taken on by women and not equally between men and women,' says Tuda, adding that Norway — and more recently Spain — are taking steps to counteract this. 'Spain has introduced a mandatory equal parental leave for both parents — they're each given six months. The mother takes the first six months, after which she returns to work, and the second parent takes the next six months. If the second parent doesn't take it, the leave goes away.' That more than one in three women here don't feel, financially, they could have a child, or another child, is also put in context, says Tuda, by the rising cost of child-rearing. 'Recent estimates from Laya Life say to raise a child up to age 21 costs €169,000.' However, delaying having children is not all down to cost. 'People are spending longer in education compared to earlier. They're also taking longer to reach job stability. Gap years abroad, unpaid internships — all valid decisions young people take to get ahead, to have better opportunities when seeking a more stable permanent job, but it also delays having children.' As do housing challenges — Tuda points out that in 10 years, the median age of buyers taking out residential property mortgages climbed by four years. 'In 2010, the median age was 33 years. In 2021, it was 37. Being older when buying property can automatically delay starting a family.' In the mix, too, says Tuda, is a sense of changing cultural norms — a move towards smaller families or even remaining childless. 'You hear this more often than you did 20 years ago.' Bonnie O'Halloran: 'One friend wants children with her boyfriend. But most people my age feel similarly to me. They don't fear pregnancy as I do — they focus more on the climate and financial aspect. None of us has stable enough careers to consider having kids. Most of us still live with our parents.' Picture: Moya Nolan Not wanting a child Of respondents to the National Women's Health Survey, who are aged under 50 and who have not yet had a child, 37% said it is unlikely they will have a child, and one-fifth are adamant they won't. One of these respondents — 25-year-old Bonnie O'Halloran from Naas — explains why, for a variety of reasons, she does not want to have children. For one, she suspects she has endometriosis — there is a family history — and she fears what pregnancy will do to her body. 'I've not wanted kids for as long as I can remember. Being a woman, it's said to you a lot — 'when will you have kids?' When you say you don't want that, you're told 'you will when you're older'. That didn't happen for me. My youngest brother was born when I was 11. I got to watch him growing up, and the responsibility of being there for another human being isn't something I wanted for myself.' 'I also saw what parenting did to my parents, not in any horrible way, but the things they had to give up. My mum went to college when she was 40 and I'm really proud of that but she couldn't do it sooner. I don't want to put that kind of pressure on myself.' Yet O'Halloran, who has a degree in illustration and currently works as a substitute teacher, loves children and thinks she might adopt when she's in her 40s. But she also sees the world's current political atmosphere, as well as climate and financial realities, as factors in deciding not to have children — a feeling she says many of her peers share: 'One friend wants children with her boyfriend. But most people my age feel similarly to me. They don't fear pregnancy as I do — they focus more on the climate and financial aspect. None of us has stable enough careers to consider having kids. Most of us still live with our parents.' While a recent CSO report indicates that our fertility rate is declining, Tuda confirms that, at 1.55 births per woman, it remains above the European average of 1.46. Among the under-50 survey respondents, who have yet to start a family, about two in five say they are 'definitely' or 'very likely' going to do so, with a further 10% saying they are 'quite likely'. Click here to read our National Women's Health Survey. The Irish Examiner Women's Health Survey 2025 Ipsos B&A designed and implemented a research project for the Irish Examiner involving a nationally representative sample of n=1,078 women over the age of 16 years. The study was undertaken online with fieldwork conducted between April 30 and May 15, 2025. The sample was quota controlled by age, socio-economic class, region and area of residence to reflect the known profile of women in Ireland based on the census of population and industry agreed guidelines. Ipsos B&A has strict quality control measures in place to ensure robust and reliable findings; results based on the full sample carry a margin of error of +/-2.8%. In other words, if the research was repeated identically results would be expected to lie within this range on 19 occasions out of 20. A variety of aspects were assessed in relation to women's health including fertility, birth, menopause, mental health, health behaviour, and alcohol consumption.

Irish Independent

a day ago

• Irish Independent

Chief of Irish medicines' watchdog appointed to take over European Union Drugs Agency

Lorraine Nolan, who was chief executive of the Health Products Regulatory Authority (HPRA) overseeing medicines in Ireland, will taken up the prestigious European role. Minister of State for European Affairs and Defence Thomas Byrne congratulated Dr Lorraine Nolan on her appointment. Dr Nolan was elected by a two-thirds majority in a secret ballot by the EUDA Management Board following a competitive public recruitment process and will take office on January 1, 2026. Minister Byrne said: "This appointment is one of which Ireland is immensely proud. Dr Nolan's distinguished career and expertise uniquely position her to guide EUDA through its important mission of addressing one of the most significant challenges facing our societies today." The European Union Drugs Agency plays a crucial role in monitoring, analysing, and responding to drug-related threats across the European Union. Under Dr Nolan's leadership, the agency will continue to strengthen its capacity to address the evolving nature of drug markets and their associated harms, he said. Minister Byrne added: 'I am confident that the EUDA will benefit enormously from Dr Nolan's expertise and vision. It is fantastic to see an Irish person elected to lead such a prominent and important EU agency. "I very much look forward to working with her in her new capacity and to continuing Ireland's strong collaboration with EUDA. 'Ireland strongly welcomes and supports the appointment of Irish nationals to senior leadership positions with EU institutions and agencies. Such appointments reflect Ireland's commitment to European integration and our ability to contribute experienced skilled professionals to key roles that benefit the entire European Union.' It was announced by the HPRA recently that Dr Nolan will step down from her position as head of the HPRA at the end of this year to pursue new career options. ADVERTISEMENT Dr Nolan has served as the Chief Executive of the HPRA for over nine years and, by the end of 2025, she will have completed two terms in this leadership role. During her tenure, she has successfully guided the organisation through a significant transformation of its key regulatory functions and an expansion of its operations, elevating the standing of the HPRA on national, European and international levels. In addition, her determined and strategic leadership during Brexit and the Covid-19 pandemic ensured the national regulator for medicines and medical devices made a vital contribution to the successful navigation of these challenges. The HPRA said Dr Nolan has been a significant contributor to the leadership of both medicines and medical device regulation at European level. Through her former position as Chair of the European Medicines Agency (EMA) Management Board (2022-2025) and her membership of the Heads of Medicines Agency (HMA) Management Group, she has held many significant roles at this level that have both defined strategy and positively enhanced delivery. Professor Michael Donnelly, Chair of the HPRA, said: 'I wish to commend Dr Nolan for her unwavering leadership and dedication to the organisation. "Her tenure has been marked by significant achievements and a hugely positive, enduring legacy. I want to express both my personal thanks and that of the Authority to Lorraine for her service and wish her every success with her future endeavours.' The Authority is commencing the process for recruitment of a new Chief Executive of the HPRA to take up the position from January 2026.